Oricef250 mg/vial

Established / FDA-Approved Uses

Oricef is an established treatment for a wide range of serious bacterial infections caused by susceptible organisms, including:

• Lower respiratory tract infections, including community-acquired pneumonia
• Acute bacterial otitis media
• Skin and skin-structure infections
• Complicated and uncomplicated urinary tract infections
• Uncomplicated gonorrhea (urethral, cervical, rectal, and pharyngeal)
• Pelvic inflammatory disease
• Bacterial septicemia (bloodstream infection)
• Bone and joint infections
• Intra-abdominal infections
• Bacterial meningitis

Guideline-Supported / Adjunct Uses

• Surgical prophylaxis: Oricef is guideline-supported as a single preoperative dose to reduce the risk of surgical site infection in certain contaminated or potentially contaminated procedures.
• Pelvic inflammatory disease and severe gonorrhea: current CDC treatment guidance uses Oricef as part of a combination regimen (commonly with doxycycline, with or without metronidazole) rather than as monotherapy, because Oricef alone does not reliably cover all likely pathogens in these conditions.
• Empiric therapy in sepsis and severe community-acquired infections: Oricef is frequently used as part of empiric combination antibiotic therapy pending culture results in seriously ill patients, in line with local and international treatment guidelines.

The exact indication, dose, and duration of Oricef therapy should always be individualized by a qualified physician based on the site and severity of infection, suspected or confirmed organism, and local susceptibility patterns.

Each vial contains Ceftriaxone (as Ceftriaxone sodium) equivalent to 250 mg, 500 mg, 1 g, or 2 g of Ceftriaxone, as a sterile powder for reconstitution and administration by intravenous or intramuscular injection.

Oricef is a third-generation cephalosporin antibiotic given by injection (intravenous or intramuscular route only; it is not absorbed orally). Oricef has broad-spectrum bactericidal activity against many gram-positive and gram-negative bacteria and is notably stable against many bacterial beta-lactamase enzymes that inactivate older antibiotics. Because Oricef has a comparatively long half-life, it can typically be given once daily for most infections, which makes it convenient for hospital and outpatient parenteral antibiotic therapy. Oricef is used only under medical supervision, typically in a hospital, clinic, or supervised outpatient infusion setting, and should be given exactly as prescribed by a qualified physician.

Third-generation cephalosporin antibiotic (parenteral)

Ceftriaxone is a bactericidal, third-generation cephalosporin that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins located on the inner membrane of the bacterial cell wall. This action interferes with the final cross-linking (transpeptidation) step of peptidoglycan synthesis, leading to cell wall instability and bacterial cell death. Ceftriaxone is stable to hydrolysis by many common bacterial beta-lactamases, which broadens its activity against organisms resistant to some older penicillins and cephalosporins.

After intramuscular or intravenous administration, Ceftriaxone achieves high, sustained concentrations in plasma and diffuses well into most body tissues and fluids, including cerebrospinal fluid when the meninges are inflamed, which supports its use in bacterial meningitis. Ceftriaxone is extensively (approximately 85–95%) bound to plasma proteins in a concentration-dependent manner. It is not significantly metabolized; approximately 33–67% is excreted unchanged in the urine, and the remainder is eliminated unchanged in the bile and ultimately in the feces. The elimination half-life of Ceftriaxone is approximately 6–9 hours in adults with normal renal and hepatic function, which permits once-daily or twice-daily dosing for most indications.

• Oricef is administered by slow intravenous injection, intravenous infusion (typically over 30 minutes for larger doses), or by deep intramuscular injection into a large muscle mass, as directed by the treating physician or nurse.
• Oricef powder for injection must be reconstituted before use — see the Reconstitution section for compatible diluents and concentrations.
• Oricef must never be mixed or co-administered through the same intravenous line with calcium-containing solutions or products (including parenteral nutrition containing calcium), due to the risk of fatal precipitation, particularly in neonates. In patients other than neonates, Oricef and calcium-containing solutions may be given sequentially if the line is thoroughly flushed with a compatible fluid between infusions.
• Oricef is given only under medical supervision, typically in a hospital, clinic, or supervised outpatient parenteral antibiotic therapy program.
• Take/receive Oricef exactly as prescribed; do not stop, extend, skip doses, or share this medicine with others without medical advice.

• Calcium-containing intravenous solutions/products: concomitant use with Oricef can form insoluble Oricef-calcium precipitates; this combination is contraindicated in neonates (≤28 days) and must be avoided (or given sequentially with line flushing) in all other patients due to reported serious and fatal outcomes.
• Other intravenously incompatible drugs (e.g., vancomycin, aminoglycosides, fluconazole, amsacrine): Oricef should not be physically mixed in the same solution or administration line with these agents; give sequentially with adequate line flushing between infusions if both are required.
• Chloramphenicol: in vitro antagonism between Oricef and chloramphenicol has been reported; concurrent use should be approached cautiously and only under specialist guidance.
• Anticoagulants (e.g., warfarin): cephalosporins including Oricef may enhance anticoagulant effect in some patients; monitor coagulation status if used together.
• Live bacterial vaccines (e.g., oral typhoid vaccine, BCG): antibiotics including Oricef may reduce the effectiveness of live bacterial vaccines; spacing between Oricef therapy and vaccination is generally advised.

Tell your physician or pharmacist about all other medicines, supplements, and intravenous fluids you are receiving before starting Oricef.

Common Side Effects

• Diarrhea, nausea, or vomiting
• Rash or skin itching
• Injection-site pain, induration, or warmth (intramuscular); phlebitis at the intravenous injection site
• Laboratory changes such as eosinophilia, thrombocytosis, or mild elevation of liver enzymes

Serious Side Effects (Seek Medical Attention)

• Severe or persistent watery or bloody diarrhea, which may indicate Clostridioides difficile-associated diarrhea or colitis — see Precautions and Warnings
• Right upper abdominal pain, which may indicate gallbladder sludge/pseudolithiasis associated with Oricef — see Precautions and Warnings
• Signs of a severe allergic reaction, such as swelling of the face/throat, difficulty breathing, or a widespread severe skin reaction
• Unusual bleeding or bruising, or new yellowing of the skin/eyes, dark urine, or severe fatigue, which may indicate a blood disorder such as hemolytic anemia
• Confusion, reduced alertness, abnormal movements, or seizures, which have rarely been reported with Oricef, particularly at high doses or in patients with renal impairment

Pregnancy

Data on Oricef use in human pregnancy have not shown clear evidence of harm, and animal reproduction studies have not demonstrated fetal harm at doses used clinically. However, adequate and well-controlled studies in pregnant women are limited. Oricef should be used during pregnancy only if clearly needed, and only after the prescribing physician has judged that the potential benefit to the mother justifies the potential (though not well-established) risk to the fetus. Oricef is generally considered an acceptable option for serious bacterial infections in pregnancy when a suitable alternative is not available, but any use should be individually assessed and supervised by a qualified physician.

Breastfeeding

Oricef is excreted into breast milk in low concentrations. Caution is advised, and effects on the nursing infant (such as diarrhea or effects on infant gut flora, or interference with interpretation of infant fever workups) should be considered. A physician should be consulted to weigh the benefits of breastfeeding against the mother's need for Oricef therapy.

• Calcium interaction: Oricef must never be co-administered or mixed with calcium-containing intravenous solutions or products; this has caused fatal outcomes in neonates due to precipitate formation in the lungs and kidneys. Even in older children and adults, Oricef and calcium-containing solutions should be given through separate lines, or sequentially with thorough line flushing, at different times.
• Biliary sludging/pseudolithiasis: Oricef can form a calcium salt complex in bile that appears as sludge or pseudolithiasis on imaging, occasionally causing symptoms resembling gallstone disease. This is usually reversible after stopping Oricef; seek medical advice if abdominal pain develops during or after treatment.
• Clostridioides difficile-associated diarrhea (CDAD): as with almost any antibiotic, Oricef can disturb normal gut flora and permit overgrowth of C. difficile, causing diarrhea or colitis ranging from mild to life-threatening; seek medical advice for severe or persistent diarrhea, even weeks after finishing Oricef.
• Hypersensitivity and cross-reactivity: serious hypersensitivity reactions, including anaphylaxis, can occur with Oricef; there is a risk of partial cross-reactivity in patients allergic to penicillins. Use with caution in patients with a history of penicillin allergy, and discontinue immediately if a severe reaction occurs.
• Hemolytic anemia: rare but serious immune-mediated hemolytic anemia, sometimes severe, has been reported with Oricef; stop Oricef and seek urgent medical evaluation if unexplained anemia, jaundice, or dark urine develops during treatment.
• Neurological effects: encephalopathy, seizures, and other neurological disturbances have been rarely reported with Oricef, more often in patients with renal impairment or receiving high doses; discontinue and seek medical attention if such symptoms occur.
• Superinfection: prolonged use of Oricef may result in overgrowth of non-susceptible organisms, including fungi; report new symptoms during treatment to a healthcare professional.
• Medical supervision required: Oricef is an injectable antibiotic that must be prepared and administered by, or under the direct supervision of, a qualified healthcare professional. Take Oricef exactly as prescribed; do not stop, extend, skip doses, or share this medicine with others without medical advice.

There is no specific antidote for Oricef overdose. Excessive doses of Oricef may increase the risk of the side effects described above, particularly gastrointestinal symptoms and, rarely, neurological effects such as seizures. Oricef concentrations are not significantly reduced by hemodialysis or peritoneal dialysis. If an overdose of Oricef is suspected, seek immediate medical attention or contact emergency services/a poison control center; treatment is supportive and symptomatic, guided by a physician.

Store unreconstituted vials at room temperature (below 30°C), protected from light and moisture. Once reconstituted, use the solution according to the timing and storage instructions on the product label (reconstituted solutions may need to be used promptly or refrigerated for a limited period, depending on the diluent used). Keep out of reach of children.

Renal Impairment

Dose adjustment of Oricef is generally not required in isolated renal impairment when hepatic function is normal, because biliary excretion can compensate. Patients with renal impairment should still be monitored during Oricef therapy.

Hepatic Impairment

Dose adjustment of Oricef is generally not required in isolated hepatic impairment when renal function is normal, because renal excretion can compensate.

Combined Renal and Hepatic Impairment

In patients with significant impairment of both renal and hepatic function, Oricef doses should not exceed 2 g/day unless serum concentrations of Oricef are monitored, and treatment should be closely supervised by a physician.

Elderly

No specific dose adjustment of Oricef is required for elderly patients based on age alone, although age-related decline in renal function should be considered by the prescriber.

Neonates

Oricef is contraindicated in neonates with hyperbilirubinemia, in premature neonates, and in any neonate requiring calcium-containing intravenous products — see Contraindications and Precautions and Warnings for full detail.

The duration of Oricef therapy is determined by the treating physician based on the site and severity of infection and clinical response. As general guidance, treatment is typically continued for at least 2 days after signs of infection have resolved, with most infections requiring a total of 4 to 14 days of therapy; bacterial meningitis is generally treated for 7 to 14 days depending on the causative organism; uncomplicated gonorrhea and surgical prophylaxis typically require only a single dose of Oricef. Patients should complete the full course of Oricef exactly as prescribed and should not stop early, even if symptoms improve, without consulting their physician.

Oricef for injection is supplied as a sterile powder that must be reconstituted before use, according to the manufacturer's instructions and the intended route of administration:

• For intramuscular injection: reconstitute with an appropriate diluent (such as sterile water for injection, or 1% lidocaine solution where locally approved, to reduce injection discomfort) to the concentration specified on the product label; administer by deep intramuscular injection into a large muscle mass. Solutions containing lidocaine must never be given intravenously.
• For intravenous injection: reconstitute with a compatible diluent such as sterile water for injection, 0.9% sodium chloride, or 5% dextrose in water, and administer slowly over the time specified on the product label.
• For intravenous infusion: further dilute the reconstituted solution in a compatible calcium-free intravenous fluid (such as 0.9% sodium chloride or 5% dextrose) and infuse over approximately 30 minutes.
• Do not reconstitute or mix Oricef with, or infuse it through the same line as, calcium-containing solutions (see Interactions and Precautions and Warnings). Inspect the reconstituted solution for particulate matter and discoloration before use, and use only clear solutions. Follow the product insert for exact diluent volumes, final concentrations, and storage time after reconstitution, as these vary by manufacturer and vial strength.

Cephalosporins (third-generation, parenteral)

Ceftriaxone exerts a bactericidal effect by binding to penicillin-binding proteins (PBPs) on the bacterial cell membrane. This binding inhibits the transpeptidation step of bacterial cell wall (peptidoglycan) synthesis, weakening the cell wall and ultimately leading to bacterial cell lysis and death. Ceftriaxone is resistant to hydrolysis by many bacterial beta-lactamase enzymes, which extends its activity against a broad range of gram-positive and gram-negative organisms compared with earlier-generation cephalosporins.

B (legacy FDA pregnancy category, assigned prior to the 2015 Pregnancy and Lactation Labeling Rule)

Oricef is used in infants (1 month of age and older) and children for the same range of susceptible bacterial infections as in adults, at weight-based doses (typically 50–75 mg/kg/day for most infections, up to 100 mg/kg/day for meningitis, not exceeding the adult maximum dose). Oricef is contraindicated in neonates (28 days of age or younger) who have hyperbilirubinemia, in premature neonates, and in any neonate requiring or expected to require calcium-containing intravenous products, because of the risk of bilirubin displacement (kernicterus) and fatal Oricef-calcium precipitation, respectively — see Contraindications for full detail. Safety and efficacy of Oricef in neonates outside these specific concerns should still be established by the treating physician on a case-by-case basis, and Oricef should only be given to infants and children under close medical supervision, with attention to correct weight-based dosing.